Pharming Group N.V. SEC filings document a foreign private issuer commercializing rare-disease medicines and reporting through Form 6-K current reports and Form 20-F annual disclosures. The filings cover financial results, revenue trends for RUCONEST® and Joenja® (leniolisib), regulatory developments for APDS, and clinical-program disclosures involving primary immunodeficiencies with immune dysregulation and napazimone (KL1333) in primary mitochondrial disease.
The company's regulatory record also includes annual-report filings, shareholder-meeting materials, auditor appointment matters, remuneration policy proposals, and authorizations related to share issuance and repurchases. These disclosures frame Pharming's governance, capital structure, commercial products, pipeline spending, licensing obligations, and rare-disease development risks.
Pharming Group N.V. (PHAR) presented positive topline results from a Phase II study of leniolisib in 13 participants with genetically identifiable primary immunodeficiencies and immune dysregulation linked to altered PI3Kδ signaling. Mean spleen volume fell 26.4% among 11 evaluable participants, and index lymph-node lesion size fell 33.7% among four. Among seven participants with impaired gas exchange at baseline, predicted DLCO increased a mean 8.0%; CT-assessed interstitial lung disease scores decreased in four of five evaluable participants, and liver stiffness improved in two of three participants with heightened baseline stiffness.
All 12 participants who completed the study enrolled in a three-year extension. Treatment-related adverse events were Grade 1, and two serious adverse events were deemed unrelated to leniolisib. One participant with a history of portal hypertension discontinued treatment early due to acute hepatitis. The safety and efficacy of leniolisib have not been established for these investigational uses.
Pharming Group N.V. (PHAR) announced that Fabrice Chouraqui will step down as Chief Executive Officer and Executive Director, effective immediately, by mutual agreement with the Board. The Board appointed Leverne Marsh, Chief Commercial Officer, and Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, also effective immediately.
Marsh will lead patient-focused operations, while Lynard will lead global corporate functions. The Board has started a formal search for a permanent successor. Pharming said its strategy, pipeline and commitment to patients remain unchanged. The company said the transition followed discussions about strategic priorities, with the Board and Chouraqui concluding that their views on advancing the strategy were not sufficiently aligned.
Pharming Group N.V. said the U.S. FDA accepted and granted Priority Review to its sNDA seeking lower doses of Joenja (leniolisib) for children aged 4 years and older who weigh 13 kg to 27 kg and have APDS. The FDA set a January 30, 2027 PDUFA target action date.
The application is supported by an open-label, multinational, single-arm Phase III study in children aged 4 to 11 years. The study reported improvements over 12 weeks in lymphadenopathy and naive B-cell levels. In September 2026, the FDA expanded Joenja's U.S. approval to children aged 4 to 11 years weighing at least 27 kg.
Pharming Group N.V. (PHAR) reports positive topline results from a single-arm, open-label Phase II trial of its oral PI3Kδ inhibitor leniolisib in 13 patients with genetically defined primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling. A late-breaking abstract of these data has been accepted for presentation at the ESID 2026 meeting in October in the Netherlands.
The study showed a favorable safety and tolerability profile, with infections as the most common adverse events and no new safety signals identified. Clinical outcomes included improvements in lymphoproliferative disease, notably a mean 26.4% reduction in spleen volume and decreases in index lesion size, indicating reduced lymphoproliferation.
Of the 13 enrolled patients, nine also had a diagnosis of common variable immunodeficiency (CVID). Pharming states that these results support continued development of leniolisib in PIDs beyond APDS and plans to present additional data at ESID 2026. Separately, the company expects to report topline Phase II results of leniolisib in CVID patients with immune dysregulation in the fourth quarter of 2026, which it says will inform plans for a potential registrational study in the broader CVID population.
Pharming Group N.V. (PHAR) announced that the U.S. FDA has approved a supplemental New Drug Application for new 40 mg and 50 mg twice-daily doses of Joenja (leniolisib) to treat children aged 4 to 11 years who weigh at least 27 kg and have activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. With this decision, Joenja becomes the first FDA‑approved treatment for children aged 4 to 11 years with APDS in the U.S. The new pediatric doses are expected to be available in October through Pharming’s specialty distribution network and patient-support infrastructure.
The approval is supported by a multinational, open-label, single‑arm Phase III study in children 4 to 11 years with APDS that showed improvements over 12 weeks in reduced lymphadenopathy and increased naïve B cells, with a safety profile consistent with prior Joenja experience and no drug‑related serious adverse events observed. Joenja is now indicated in the U.S. for adult and pediatric patients 4 years and older who weigh 27 kg or more.
Pharming Group N.V. reports the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following inclusion on the Japan National Health Insurance drug price list. Japan is the first market where Joenja is commercially available for children aged 4 to 11. OrphanPacific, Inc. is the Marketing Authorization Holder and, under its agreement with Pharming, is responsible for supply and distribution in Japan. Joenja is an oral PI3Kδ inhibitor already approved to treat APDS in adults and children 12 years and older in multiple countries, and leniolisib is also under regulatory review for pediatric APDS in several additional markets.
Pharming Group N.V. reported second quarter 2026 total revenues of US$90.2 million, down 3% from US$93.2 million a year earlier. RUCONEST® generated US$72.3 million, 10% lower year on year but 24% above the first quarter, while Joenja® revenues rose 40% to US$17.9 million. Operating profit fell to US$1.3 million from US$10.8 million, pressured by US$4.9 million in manufacturing-related inventory impairments and US$1.7 million in costs tied to closing the Évry, France site, resulting in net profit of US$1.6 million.
For the first half of 2026, revenues declined 6% to US$162.7 million, with RUCONEST down 12% to US$130.7 million and Joenja up 37% to US$32.0 million. The company posted an operating loss of US$3.6 million versus a US$3.8 million profit in 2025 and a net loss of US$3.6 million. Cash and cash equivalents were US$158.3 million at June 30, 2026.
Pharming revised 2026 total revenue guidance to US$375–395 million (0–5% growth), a US$30 million reduction, while improving operating expense guidance by US$15 million to US$315–320 million. Management expects RUCONEST to stabilize and return to growth in the second half and highlights strong Joenja momentum, including European Commission marketing authorization, approvals in Canada and South Korea, and a U.S. pediatric sNDA with a PDUFA date of October 24, 2026. Two Phase II leniolisib trials in primary immunodeficiencies, including CVID, are expected to deliver data in the fourth quarter of 2026.
Pharming Group N.V. reports that the U.S. FDA has accepted its resubmitted supplemental New Drug Application (sNDA) for Joenja (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The resubmission follows a Complete Response Letter issued on January 30, 2026 and includes additional analytical data requested by the FDA.
The application seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing at least 27 kg, and the FDA has set a PDUFA target action date of October 24, 2026. The filing is supported by Phase III data showing 12-week improvements in lymphadenopathy and naïve B cells, with only mild to moderate treatment-emergent adverse events and no drug-related serious events. Pharming also plans a separate sNDA for lower-weight children later in 2026.
Pharming Group N.V. reported the results of its 2026 Annual General Meeting of Shareholders, where shareholders approved all proposals presented. KPMG Accountants N.V. was appointed as independent external auditor for the financial years 2026 through 2028, replacing Deloitte Accountants B.V. as of May 28, 2026.
Deloitte’s audit reports on the consolidated financial statements for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications, and the company reports no disagreements or reportable events with Deloitte, other than previously disclosed material weaknesses in internal control over financial reporting. Shareholders also approved amendments to the Board remuneration policy, and renewed authorizations for the Board to issue and repurchase shares.
Pharming Group N.V. received European Commission marketing authorization for Joenja® (leniolisib), making it the first approved treatment for activated PI3K delta syndrome (APDS) in the European Union for adults and children aged 12 and older. APDS is a rare primary immunodeficiency, affecting about 1 to 2 people per million worldwide and often diagnosed with a median delay of seven years. The approval, which is valid in all 27 EU Member States plus Norway, Iceland and Liechtenstein, is based on a multinational, triple-blind, placebo-controlled Phase II/III trial in 31 patients and long-term extension data from 37 patients treated for a median of three years. Pharming expects its first European launch in Germany in Q3 2026, with further launches following national reimbursement negotiations, adding to existing Joenja approvals in the U.S., U.K., Japan, Australia and Israel.